Literature DB >> 30802985

Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.

Paola Todesca1,2, Luca Marzi3, Rosina Maria Critelli1,2, Biagio Cuffari1, Cristian Caporali4, Laura Turco1,2, Giovanni Pinelli5, Filippo Schepis1, Lucia Carulli1,2, Nicola de Maria1, Federico Casari4, Riccardo Scaglioni4, Erica Villa1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30802985     DOI： 10.1002/hep.30588

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  4 in total

1.  Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.

Authors:  Elisabetta Goio; Luca Ielasi; Francesca Benevento; Matteo Renzulli; Francesco Tovoli
Journal:  Hepat Oncol       Date:  2020-07-03

Review 2.  Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy.

Authors:  Junjie Liu; Haisu Tao; Tong Yuan; Jiang Li; Jian Li; Huifang Liang; Zhiyong Huang; Erlei Zhang
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

3.  TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition.

Authors:  Amélie Marguier; Caroline Laheurte; Benoît Lecoester; Marine Malfroy; Laura Boullerot; Adeline Renaudin; Evan Seffar; Abhishek Kumar; Charlée Nardin; François Aubin; Olivier Adotevi
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

4.  Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.

Authors:  Atsushi Ono; Hiroshi Aikata; Masami Yamauchi; Kenichiro Kodama; Waka Ohishi; Takeshi Kishi; Kazuki Ohya; Yuji Teraoka; Mitsutaka Osawa; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Daiki Miki; Tomokazu Kawaoka; Hiromi Abe-Chayama; Peiyi Zhang; Songyao Liu; Grace Naswa Makokha; Masataka Tsuge; Michio Imamura; C Nelson Hayes; Kazuaki Chayama
Journal:  Ther Adv Med Oncol       Date:  2020-05-20       Impact factor: 8.168
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.